Cognition Therapeutics, Inc. · NASDAQ:CGTX
Cognition Therapeutics — Investor Presentation (August 2026)
19 slides from Cognition Therapeutics's investor presentation, August 2026
Slide 1: Zervimesine in DLB Psychosis
COGNITION THERAPEUTICS · NASDAQ: CGTX Zervimesine in DLB Psychosis An Investigational Oral Therapy Advancing Toward Registrational Development August 2026 · Investor Presentation https://cogrx.com
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or current
Slide 3: Cognition Therapeutics Fundamentals
Cognition Therapeutics Fundamentals Clinical-stage CNS drug developer — one lead asset, two strategic indications Corporate Profile Financial Position · As of June 30, 2026 Ticker / Exchange CGTX / NASDAQ CASH & EQUIVALENTS CASH RUNWAY OBLIGATED NIA FUNDS Headquarters Purchase, NY ~$34.8M Into Q4 $2
Slide 4: Investment Highlights
Investment Highlights Five pillars shaping the Cognition Therapeutics investment case today Unmet Need Clinical Results Oral Profile Focused Strategy AD Catalyst No approved SHIMMER Phase 2: Once-daily pill — Registrational program START Phase 2 data in medications • Benefit across accessible and in
Slide 5: Capital Priorities and Near-Term Objectives
Capital Priorities and Near-Term Objectives How the company is allocating resources — and what investors are funding FDA Division of Registrational Study 01 Psychiatry 02 Preparations 03 START Execution 04 Capital Efficiency Met May 20, 2026 to Finalize DLB psychosis Maintain progress in fully Focus
Slide 6: Understanding DLB Psychosis
Understanding DLB Psychosis A progressive and under-recognized disease with no approved treatments DLB Symptom Domains and ADLs What is Dementia with Lewy Bodies (DLB)? • 2nd most common cause of dementia after Alzheimer's Behavior / Psychosis Focus Hallucinations, delusions, agitation, anxiety • Af
Slide 7: Why DLB Psychosis Matters
Why DLB Psychosis Matters A high-burden, high-prevalence symptom cluster with no approved treatment options ~80% ZERO #1 of DLB patients experience psychosis FDA-approved drugs specifically for psychosis is a leading reason DLB (hallucinations and/or delusions)(1) DLB psychosis today patients move t
Slide 8: Current Landscape for DLB Neuropsychiatric Symptoms
Current Landscape for DLB Neuropsychiatric Symptoms The existing options are inadequate — and most carry serious risks for Lewy body patients Approach How Used Key Limitation in DLB Traditional Antipsychotics Can trigger severe motor reactions (neuroleptic sensitivity) — Off-label, commonly tried (e
Slide 9: DLB Treatment Landscape: A Patchwork of Off-label Drugs
DLB Treatment Landscape: A Patchwork of Off-label Drugs The existing options are inadequate — and most carry serious risks for Lewy body patients Symptom Domain Off-label Options Key Limitation in DLB • Traditional antipsychotics (haloperidol); • Atypical antipsychotics (pimavanserin, Atypicals can
Slide 10: What's Next: Focusing on DLB Psychosis
What’s Next: Focusing on DLB Psychosis A strategic decision driven by data, regulatory feedback, and capital discipline SHIMMER FDA Type C FDA 03 Market Opportunity Phase 2 Data Meeting (Jan 2026) Meeting (May 2026) Strongest observed FDA confirmed FDA appreciated MoA DLB psychosis market is effects
Slide 11: Zervimesine (CT1812) — Product Profile
Zervimesine (CT1812) — Product Profile An oral small molecule with a practical profile for a population that needs it most Route & Dosing Target Patient • Oral, once-daily administration • DLB patients with psychosis • 100 mg dose established based on Phase 2 study work • Ages 50-85 in Phase 2 studi
Slide 12: How Zervimesine is Designed to Work
How Zervimesine is Designed to Work Targeting the biology of DLB — treating the underlying disease Toxic proteins Neuron signals Psychosis & Zervimesine Accumulate are blocked symptoms emerge acts on disease biology in DLB brain1 synaptic breakdown hallucinations, delusions blocks toxic protein befo
Slide 13: SHIMMER: Phase 2 Study Design
SHIMMER: Phase 2 Study Design A grant-funded Phase 2 study designed to detect efficacy across DLB symptom domains Objectives Enrollment Treatment Period — 6 Months Assessments Identify efficacy • Age 50-85 Randomized 1:1:1 • Safety & tolerability Confirm safety profile • DLB diagnosis • Behavior
Slide 14: SHIMMER Phase 2: Key Findings
SHIMMER Phase 2: Key Findings The strongest effects were seen in neuropsychiatric symptoms Strong Early Data Supporting Percent Slowing of Symptoms at Day 182 CT1812 for DLB Pooled Zervimesine (100+300mg) vs. Placebo; ITT Population Behavior Cognition Function Movement 1. Galvin et al. Phase 2 study
Slide 15: From Phase 2 Results to Registrational Program
From Phase 2 Results to Registrational Program Plans for the next study design — and why the path is credible Registrational Study in Development (Next Step) Indication DLB psychosis (hallucinations, delusions) 80% of DLB patients have psychosis symptoms FDA Alignment Overseen by FDA Division of Psy
Slide 16: Regulatory Progress and Next Steps
Regulatory Progress and Next Steps Structured FDA dialogue has been ongoing — the company has completed key preparatory meetings DLB Expanded Access Program Opens Mid-2025 ✓ Done Patients and families driven to maintain access. Program filled to capacity immediately — signaling physician and caregiv
Slide 17: Clinical Studies in Alzheimer's Disease
Clinical Studies in Alzheimer’s Disease Strong results in mild-to-moderate Alzheimer’s disease in SHINE study – strongest in low p-tau217 SHINE (complete) Treatment Period — 6 Months SHINE Results in Below Median p-Tau217 Population • Age 50-85 Randomized 1:1:1 • AD confirmed with PET or Zervimesine
Slide 18: START Trial: MCI through Mild Alzheimer's Disease
START Trial: MCI through Mild Alzheimer’s Disease 545-participant study with option for concomitant mAb use START (ongoing) Treatment Period — 18 Months START Insights • Age 50-85 Randomized 1:1:1 • Appx 15% of participants are on stable background of • AD confirmed immunotherapeutics with PET or Ze
Slide 19: Highly Experienced Management Team Coupled with External Support and Third-Party Validation
Highly Experienced Management Team Coupled with External Support and Third-Party Validation A team with CNS experience, backed by NIH, analyst consensus, and patient demand Key Leadership External Validation & Support NIH/NIA Grant Funding Lisa Ricciardi >$170M in non-dilutive grants. $25.6M obligat
Cognition Therapeutics — Investor Presentation (August 2026) on 6ix